Zentalis Pharmaceuticals Inc’s filing revealed that its 10% Owner Matrix Capital Management Comp unloaded Company’s shares for reported $9.97 million on Dec 15 ’25. In the deal valued at $1.33 per share,7,500,000 shares were sold. As a result of this transaction, Matrix Capital Management Comp now holds 6,459,973 shares worth roughly $9.04 million.
Then, Myers Scott Dunseth bought 21,000 shares, generating $29,373 in total proceeds. Upon buying the shares at $1.40, the Director now owns 281,192 shares.
Before that, Bruns Ingmar bought 20,000 shares. Zentalis Pharmaceuticals Inc shares valued at $45,656 were divested by the Chief Medical Officer at a price of $2.28 per share. As a result of the transaction, Bruns Ingmar now holds 36,629 shares, worth roughly $51280.6.
Wedbush upgraded its Zentalis Pharmaceuticals Inc [ZNTL] rating to a Neutral from a an Underperform in a research note published recently. A number of analysts have revised their coverage, including UBS’s analysts, who decreased its forecast for the stock in mid June from “a Buy” to “a Neutral”. Wells Fargo also remained covering ZNTL and has decreased its forecast on June 18, 2024 with a “an Equal weight” recommendation from previously “an Overweight” rating. Wedbush revised its rating on June 18, 2024. It rated ZNTL as “an Underperform” which previously was an “a Neutral”.
Price Performance Review of ZNTL
On Monday, Zentalis Pharmaceuticals Inc [NASDAQ:ZNTL] saw its stock unchanged to $1.4. Over the last five days, the stock has lost -0.71%. Zentalis Pharmaceuticals Inc shares have fallen nearly -60.00% since the year began. Nevertheless, the stocks have fallen -53.80% over the past one year. While a 52-week high of $3.33 was reached on 01/03/25, a 52-week low of $1.01 was recorded on 04/09/25.
Levels Of Support And Resistance For ZNTL Stock
The 24-hour chart illustrates a support level at 1.3582, which if violated will result in even more drops to 1.3164. On the upside, there is a resistance level at 1.4386. A further resistance level may holdings at 1.4772.
How much short interest is there in Zentalis Pharmaceuticals Inc?
A steep rise in short interest was recorded in Zentalis Pharmaceuticals Inc stocks on 2025-11-28, growing by 0.14 million shares to a total of 5.13 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 4.99 million shares. There was a rise of 2.7%, which implies that there is a positive sentiment for the stock.
